These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27431016)

  • 1. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
    Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR
    Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
    Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
    Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.
    Cadot S; Audebert C; Dion C; Ken S; Dupré L; Largeaud L; Laurent C; Ysebaert L; Crauste F; Quillet-Mary A
    PLoS Med; 2024 Jul; 21(7):e1004430. PubMed ID: 39037964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
    Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
    Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
    Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
    Guinn D; Lehman A; Fabian C; Yu L; Maddocks K; Andritsos LA; Jones JA; Flynn JM; Jaglowski SM; Woyach JA; Byrd JC; Johnson AJ
    Cancer Med; 2017 Apr; 6(4):778-787. PubMed ID: 28299881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations.
    Li Y; Mao M; Liu H; Wang X; Kou Z; Nie Y; Wang Y; Wang Z; Huang Q; Lang T; Gu Z; An L; Zhang X; Fu L
    Mol Cell Probes; 2019 Oct; 47():101436. PubMed ID: 31425738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.
    Li S; Moffett HF; Lu J; Werner L; Zhang H; Ritz J; Neuberg D; Wucherpfennig KW; Brown JR; Novina CD
    PLoS One; 2011 Mar; 6(3):e16956. PubMed ID: 21408091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
    Morande PE; Sivina M; Uriepero A; Seija N; Berca C; Fresia P; Landoni AI; Di Noia JM; Burger JA; Oppezzo P
    Blood; 2019 May; 133(19):2056-2068. PubMed ID: 30814061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
    Burger JA; Buggy JJ
    Leuk Lymphoma; 2013 Nov; 54(11):2385-91. PubMed ID: 23425038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Ibrutinib Therapy Reverses CD8
    Parry HM; Mirajkar N; Cutmore N; Zuo J; Long H; Kwok M; Oldrieve C; Hudson C; Stankovic T; Paneesha S; Kelly M; Begum J; McSkeane T; Pratt G; Moss P
    Front Immunol; 2019; 10():2832. PubMed ID: 31921116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.
    Wu Z; Wang L; Fan L; Tang H; Zuo X; Gu D; Lu X; Li Y; Wu J; Qin S; Xia Y; Zhu H; Wang L; Xu W; Li J; Jin H
    Mol Oncol; 2022 Aug; 16(16):2920-2935. PubMed ID: 35811334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
    Maharaj K; Powers JJ; Achille A; Deng S; Fonseca R; Pabon-Saldana M; Quayle SN; Jones SS; Villagra A; Sotomayor EM; Sahakian E; Pinilla-Ibarz J
    Blood Adv; 2018 Nov; 2(21):3012-3024. PubMed ID: 30425065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
    Wolf C; Garding A; Filarsky K; Bahlo J; Robrecht S; Becker N; Zucknick M; Rouhi A; Weigel A; Claus R; Weichenhan D; Eichhorst B; Fischer K; Hallek M; Kuchenbauer F; Plass C; Döhner H; Stilgenbauer S; Lichter P; Mertens D
    Int J Cancer; 2018 Jan; 142(2):322-333. PubMed ID: 28921505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
    Herman SE; Mustafa RZ; Gyamfi JA; Pittaluga S; Chang S; Chang B; Farooqui M; Wiestner A
    Blood; 2014 May; 123(21):3286-95. PubMed ID: 24659631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.